Healthcare in 2022: what you need to know
With the Covid-19 pandemic sending shockwaves in the hospital sector, healthcare providers will continue looking for ways to slowly rebuild …
Post
-
-
IceCure secures IRB approval for ChoICE Study in US
IceCure Medical has received the Institutional Review Board (JHM-IRB) of West Cancer Center & Research Institute in Germantown, Tennessee, US, approval …
-
Polyrizon finalises five site agreements for Nasarix trial
Polyrizon has completed agreements with five sites for its planned clinical trial evaluating Nasarix Allergy Blocker (PL-14) in patients with …
-
Charles River and MVC to develop enterovirus vaccine
Charles River Laboratories International and Medigen Vaccine Biologics (MVC) have entered a collaboration to support the characterisation along with validation …
-
FDA clears Empatica’s platform for Parkinson’s monitoring
Empatica has received the US Food and Drug Administration (FDA) 510(k) clearance for its Health Monitoring Platform for Parkinson’s, enabling …
-
Novo Nordisk commences study for reduced Wegovy pill dosing
Novo Nordisk has begun a late-stage clinical trial to evaluate whether lower doses of its oral pill, Wegovy, can still …
-
Healthcare in 2022: what you need to know
With the Covid-19 pandemic sending shockwaves in the hospital sector, healthcare providers will continue looking for ways to slowly rebuild …
-
SandboxAQ introduces AQPotency for virtual drug screening
US-based SandboxAQ has introduced AQPotency, a Large Quantitative Model (LQM) designed to virtually screen and predict the potential of drug …
-
First patient treated in FDA IDE study of Aqua Medical’s PIMA device
Aqua Medical has treated the first West Coast patient in the RESTORE-I trial, a Food and Drug Administration (FDA)-approved investigational …
-
Enrolment concludes in Lynch’s Phase II rhPDGF-BB study
Lynch Regenerative Medicine has completed participant enrolment in a Phase II clinical trial assessing the recombinant human pure platelet-derived growth …
-
BeOne Medicines and partners renew Brukinsa access programme for CLL
BeOne Medicines, the BeOne Care Foundation, and The Max Foundation have extended their partnership to expand Brukinsa (zanubrutinib) access for …
-
J&J secures FDA clearance for MONARCH QUEST 3 bronchoscopy system
Johnson & Johnson (J&J) has received the US Food and Drug Administration (FDA) 510(k) clearance for the MONARCH QUEST 3 …
-
Leal Therapeutics raises $30m to fund schizophrenia and ALS trials
Leal Therapeutics has completed a $30m extension of its Series A financing to support advancement of its investigational therapies for …
-
Fulcrum and Slate Medicines sign merger agreement
Fulcrum Therapeutics and Slate Medicines have signed a definitive agreement to merge in an all-stock transaction backed by a $245m …
-
Nanochon secures Panamá’s approval for trial of knee cartilage implant
Nanochon has secured the Panamá’s Ministry of Health approval to begin its first-in-human trial of Chondrograft, an implant intended to …
-
FDA approves ArkBio’s ziresovir for Phase II trial in severe RSV
Shanghai Ark Biopharmaceutical (ArkBio) has received approval from the US Food and Drug Administration (FDA) to begin a Phase II …
-
FDA grants fast track status to Phanes’ spevatamig for advanced BTC
Phanes Therapeutics has received fast track designation from the US Food and Drug Administration (FDA) for spevatamig to treat patients …
